Results 161 to 164 of about 9,620 (164)

Canakinumab for the treatment of TNF-receptor associated periodic syndrome

Expert Review of Clinical Immunology, 2017
exaly  

Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial

Diabetes and Metabolism, 2013
exaly  

Canakinumab

Reactions Weekly, 2014
openaire   +1 more source

Canakinumab

2013
openaire   +1 more source